BNET Industries
Market Cap:$4.6M
Last Fiscal Year Sales:$589.0K
- Public
- US
Dow Jones Description
Calypte Biomedical Corporation is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the Aware(R) HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
CFO & Vice President
Richard D. BrounsteinNumber of Employees 1
Contact Information
5 Centerpointe Drive
Suite 400
Lake Oswego, Oregon 97035
(971) 204-0282
Peer Companies
NAICS Code Analytical Laboratory Instrument Manufacturing: 334516
Recent Events
-
Calypte Biomedical Announces Changes to its Board of Directors
News & Analysis
Filter by
calypte biomedical corp. and sec - All News and Analysis
Calypte Biomedical To Hold Investor Call on Tuesday, September 18th To Discuss Significant Corporate Development
LAKE OSWEGO, Ore. -- Calypte Biomedical Corporation (OTCBB: CBMC), a manufacturer and marketer of medical diagnostic tests for the rapid detection of antibodies to the human immunodeficiency virus HIV, announced today that it will hold a conference call for the investment community and other interested parties on Tuesday, September 18,...
Our-Street.com files addendum to complaint with SEC against Calypte Biomedical Corporation.
M2 PRESSWIRE-12 November 2003-Our-Street.com: Our-Street.com files addendum to complaint with SEC against Calypte Biomedical CorporationC1994-2003 M2 COMMUNICATIONS LTD RDATE:11122003 Alameda, CA -- Our-Street.com, an Internet-based, public company watchdog, announced today that it has filed an addendum to the complaint it...
Calypte Biomedical Corporation Files Preliminary Proxy Statement
Business Editors/Health/Medical Writers ALAMEDA, Calif.--BUSINESS WIRE--April 4, 2003 Calypte Biomedical Corporation (OTCBB:CALY) today announced that it has filed a preliminary proxy statement with the Securities and Exchange Commission seeking stockholder approval to amend the Company's Amended and Restated Certificate of Incorporation to implement a reverse split of the...
Calypte Announces Results of Special Shareholder Meeting and Preliminary Unaudited Fourth Quarter 2002 Results
Business Editors ALAMEDA, Calif.--BUSINESS WIRE--Feb. 18, 2003 Calypte Biomedical Corporation (OTCBB:CALY), the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test, announced the results of...
Calypte Updates Guidance for Current Quarter and 2002; First Quarter Results To Be Released May 1st
Business Editors/Health & Medical Writers ALAMEDA, Calif.--BW HealthWire--March 28, 2002 Calypte Biomedical Corporation (OTCBB:CALY), a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services, today revised guidance for the first fiscal quarter of 2002 and updated information regarding its financial position. Based...
Calypte Biomedical Presents At Wall Street Analyst Forum; Shares plans for future growth with analysts, portfolio managers at key New York conference
Business/Technology Editors ALAMEDA, Calif.--BW HealthWire--Feb. 19, 2002 Calypte Biomedical Corporation (OTCBB: CALY), a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services, shared its plans for future growth with several dozen analysts and portfolio managers late last week at The Wall Street...
Calypte Biomedical to Present At Wall Street Analyst Forum; Management to Address Analysts, Portfolio Managers On February 14 At Institutional Conference
Business Editors/Health & Medical Writers ALAMEDA, Calif.--BW HealthWire--Feb. 12, 2002 Calypte Biomedical Corporation (OTCBB:CALY), a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services, today announced that its senior management will be making a presentation to analysts and portfolio managers at The...
Calypte Announces Preliminary 2001 Operating Results
Business Editors and Health/Medical Writers ALAMEDA, Calif.--BW HealthWire--Feb. 7, 2002 Revenues More Than Double and Margins are Sharply Higher, Setting Quarterly, Annual Records: February 12 Conference Call-In Numbers Established Calypte Biomedical Corporation (OTCBB:CALY), a public healthcare company dedicated to the development and commercialization of urine-based...
Calypte Announces Extended Expiration Dating for HIV-1 Western Blot Products
Business Editors and Health/Medical Writers ALAMEDA, Calif.--BW HealthWire--Nov. 29, 2001 Calypte Biomedical Corporation (OTCBB:CALY) today announced that it secured FDA approval for extended dating of its Cambridge HIV-1 Western Blot products from 12 months to 15 months. Obtaining extended dating was a critical milestone in the Company's...
Calypte Reports Third Quarter 2001 Financial Results; Revenues Increase 75% Compared With Third Quarter 2000
Business Editors/Health & Medical Writers ALAMEDA, Calif.--BW HealthWire--Oct. 18, 2001 Calypte Biomedical Corporation (OTCBB:CALY) announced today that its revenues for the third quarter ended September 30, 2001 increased 75% to $1,465,000 compared to $835,000 for the same period last year. Revenues for the nine months ended September 30,...
- 1
- 2
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Richard D. Brounstein | CFO & Vice President |
| Ronald W. Mink | Chief Science Officer |
| Theodore R. Gwin | CFO |
| Richard Van Maanen | Vice President, Operations |
| Luc Montagnier | Director, Oncology |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Anthony J. Cataldo | Executive Chairman |
| John J. Dipietro | Board of Directors |
| Julius R. Krevans | Board of Directors |
| Paul E. Freiman | Board of Directors |
| Zafar I. Randawa | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Calypte Biomedical Corporation | CFO & Vice President | Current |
| Organization | Position | Status |
|---|---|---|
| Calypte Biomedical Corporation | Chief Science Officer | Current |
| Organization | Position | Status |
|---|---|---|
| Calypte Biomedical Corporation | CFO | Current |
| Organization | Position | Status |
|---|---|---|
| Calypte Biomedical Corporation | Vice President, Operations | Current |
| Organization | Position | Status |
|---|---|---|
| Calypte Biomedical Corporation | Director, Oncology | Current |
| Calypte Biomedical Corporation | Director, Oncology | Former |
Anthony J. Cataldo, age 55 became our Chief Executive Officer and Chairman in September 2006. During the past five (5) years, Mr. Cataldo has served as non-executive chairman of the board of directors of BrandPartners Group, Inc. (OTC BB:BPTR) a provider of integrated products and services dedicated to providing financial services and traditional retail clients with turn-key environmental solutions from October 2003 through August 2006. Mr. Cataldo also served as non-executive co-chairman of the board of MultiCell Technologies, Inc. (OTC BB: MUCL) a supplier of functional, non-tumorigenic immortalized human hepatocytes from February 2005 through July 2006. Mr. Cataldo has also served as executive chairman of Calypte Biomedical Corporation (AMEX: HIV), a publicly traded biotechnology company, involved in development and sale of urine based HIV-1 screening test from May 2002 through November 2004. Prior to that, Mr. Cataldo served as the Chief Executive Officer and Chairman of the Board of Directors of Miracle Entertainment, Inc., a Canadian film production company, from May 1999 through May 2002 where he was the executive producer or producer of several motion pictures. From August 1995 to December 1998, Mr. Cataldo served as President and Chairman of the Board of Senetek, PLC (OTC BB:SNTKY), a publicly traded biotechnology company involved in age-related therapies.
| Organization | Position | Status |
|---|---|---|
| Calypte Biomedical Corporation | Executive Chairman | Current |
| Calypte Biomedical Corporation | Board of Directors | Current |
| VoIP, Inc. | CEO and Chairman | Former |
| Miracle Entertainment, Inc | Chief Executive Officer | Former |
| Internet Systems | President | Former |
| Miracle Entertainment, Inc | Producer | Former |
| Senetek PLC | Chairman of the Board | Former |
| BrandPartners Group | Chairman | Former |
| Miracle Entertainment, Inc | Chairman of the Board of Directors | Former |
| Multicell Technologies, Inc. | Chairman of the Board | Former |
| BrandPartners Group | Board of Directors | Former |
| Organization | Position | Status |
|---|---|---|
| Calypte Biomedical Corporation | Board of Directors | Current |
| Tripath Technology, Inc. | Chief Financial Officer | Former |
| Tripath Technology, Inc. | Vice President, Finance & Administration | Former |
| University of Chicago | M.B.A. | Former |
Company since May 1994 and as Chairman of the Board of Directors of our Company since February 1999. Dr. Krevans served as Chancellor of the University of California, San Francisco from July 1982 until May 1993. Prior to his appointment as Chancellor, Dr. Krevans served as a Professor of Medicine and Dean of the School of Medicine at the University of California, San Francisco from 1971 to 1982. Dr. Krevans is a member of the Institute of Medicine, National Academy of Sciences, and led its committee for the National Research Agenda on Aging until 1991. Dr. Krevans also serves on the Board of Directors and the compensation committee of the Board of Directors of Calypte Biomedical corporation (Calypte), a publicly held corporation. Dr.Krevans has a B.S. degree and a M.D. degree, both from New York University.
| Organization | Position | Status |
|---|---|---|
| National Academy of Sciences | Member | Current |
| Neoprobe Corporation | Chairman | Current |
| Neoprobe Corporation | Board of Directors | Current |
| Calypte Biomedical Corporation | Board of Directors | Current |
| University of California, San Francisco | Director of International Medical Care | Former |
| University of California, San Francisco | Professor of Medicine | Former |
| New York University | M.D. Degree | Former |
| New York University | B.S. Degree | Former |
| Johns Hopkins University School of Medicine | residency in Medicine | Former |
| Organization | Position | Status |
|---|---|---|
| Syntex Corporation | Chief Executive Officer | Current |
| Neurobiological Technologies, Inc. | President & CEO | Current |
| Scigen Ltd | Leading Independant Director | Current |
| Penwest Pharmaceuticals, Co. | Chairman | Current |
| Omware, Inc. | Director | Current |
| Phytos Inc | Director | Current |
| NovaBay Pharmaceuticals, Inc. | Board of Directors | Current |
| Scigen Ltd | Board of Directors | Current |
| NeoPharm, Inc. | Board of Directors | Current |
| Novacal Pharmaceuticals, Inc. | Board of Directors | Current |
| Calypte Biomedical Corporation | Board of Directors | Current |
| Neurobiological Technologies, Inc. | Board of Directors | Current |
| Syntex Corporation | chairman | Former |
| Penwest Pharmaceuticals, Co. | Board of Directors | Former |
| Calypte Biomedical Corporation | Director | Former |
| Nti, Inc. | Director | Former |
| Fordham University | B.S. Degree In Pharmacy | Former |
| Organization | Position | Status |
|---|---|---|
| Calypte Biomedical Corporation | Board of Directors | Current |
Industry Transcripts by Seeking Alpha
-
Cantel Medical Corp. F1Q10 (Qtr End 10/31/09) Earnings Call Transcript
on Dec 09, 2009about CMN
-
The Cooper Companies, Inc. F4Q09 (Qtr End 10/31/09) Earnings Call Transcript
on Dec 08, 2009about COO
-
Medtronic Inc. F2Q10 (Qtr End 10/30/09) Earnings Call Transcript
on Nov 24, 2009about MDT
-
ZOLL Medical Corporation F4Q09 (Qtr End 27/09/09) Earnings Call Transcript
on Nov 11, 2009about ZOLL
-
RadNet, Inc. Q3 2009 Earnings Call Transcript
on Nov 09, 2009about RDNT
IndustryTop Rated
- Why So Many Insured People Have Big Medical Debts 5 votes
- Hospital Chain's Turnaround Raises Health Spending 3 votes
- Healthcare Roundup: Medical Office Space in Demand, Blues Companies See Lower Income, Two Sides of Health Insurance, and More 3 votes
- Physicians Finally Getting Help to Become Medical Homes 2 votes
- Right-Sizing The Physician Workforce 2 votes


